Oct. 22, 2025 / PRZen / VENICE, Calif. — Keebos, the crossbody phone case brand, announced full compatibility for iPhone 17, iPhone 17 Air, iPhone 17 Pro, and iPhone 17 Pro Max, bringing its signature crossbody phone case to Apple’s newest lineup. In addition to iPhone, Keebos also makes crossbody cases for all Samsung and Google Pixel models, giving customers a consistent, hands free experience across the leading smartphone brands.
Pricing & Availability
MSRP starts at $49.90. In the United States, cases for iPhone 17, iPhone 17 Air, iPhone 17 Pro, and iPhone 17 Pro Max are available now at keebos.com. Orders ship from Los Angeles with typical U.S. delivery in 3 to 5 business days. International shipping is available for $9.90 with delivery generally in 6 to 10 days.
Why Keebos – The Iconic Crossbody Phone Case Brand
The crossbody phone cases combine a protective case with a detachable and adjustable strap, so users can wear a phone crossbody or around the neck, then switch back to a classic case in seconds. A sealable wallet on the back that holds up to six cards. Protection includes four corner bumper construction and a 3 mm raised lip to help protect screens and cameras. This way of carrying a phone simplifies days on the go for travelers, parents, creators, and anyone who wants essentials within easy reach.
Fast, Free Shipping From Los Angeles
All U.S. orders include free shipping from Keebos’ Venice Beach facility, with typical delivery in 3 to 5 business days. International customers can select the $9.90 option at checkout, which typically arrives in 6 to 10 days.
Sustainability With Every Purchase
For each case purchased, Keebos funds the planting of one tree through organizations like One Tree Planted, a registered 501(c)(3) organization. Packaging is designed to be eco conscious & biodegradable to help reduce waste from shipment to unboxing.
Styles For Every Look
With a variety of straps and seasonal colorways, the California based brand offers a wide range of styles to fit any outfit or occasion. Each strap is adjustable for a custom fit & fully detachable for maximum flexibility, with options for all current iPhone, Samsung, and Google Pixel users. The brand also features verified customer testimonials on its reviews page and storefronts, reflecting consistent feedback on convenience, comfort, and the peace of mind that comes from keeping phones secure & accessible.
Key Features
Available for iPhone 17, iPhone 17 Air, iPhone 17 Pro, and iPhone 17 Pro Max.
Oct. 22, 2025 / PRZen / PRAGUE & NEWARK, Del. — The OpenSSL Corporation and the OpenSSL Foundation celebrate the success of the inaugural OpenSSL Conference, held in Prague, October 7-9. This was the first time in the history of the OpenSSL Project that the full community met in person. Developers, legal experts, and users from academics, committers, distributions, individuals, large businesses, and small businesses came together to discuss project direction, share experience, and collaborate on the future of secure digital communication.
By the numbers:
Over 400 participants from 30+ countries, including the United States, Germany, Japan, India, Canada, France, the UK, and the Czech Republic.
95 % attendance rate
113 speakers and 97 sessions
Participation from major organisations such as Microsoft, Cisco, Red Hat, IBM, Intel, and others
Government and academic institutions, including the Brno University of Technology, Eindhoven University of Technology, Masaryk University, Rochester Institute of Technology, Tampere University, Trinity College Dublin, the University of Illinois at Chicago, and the University of Waterloo, among others, also participated. Attendees included CISOs, engineers, researchers, policymakers, lawyers, and open-source maintainers, all advancing secure and open communication technologies.
“[The] OpenSSL conference 2025 was one of my most technically enriching experiences. I learned a lot through delivering my talk, attending others’, getting feedback and going around the booths,” said Nikita Tripathi, Software Engineer at Qualcomm. “Even more remarkable was how well-coordinated and organised it was, to be able to handle around 450 people on time. Kudos to the team for making it happen!”
Vaclav (Vashek) Matyas, Head of the Centre for Research on Cryptography and Security at Masaryk University Brno, said, “Three great days with the right people from various communities supporting good crypto, open source, and reliable security. Many nice talks, relevant networking and smooth organization. I’m looking forward to the next edition – let me know the dates soon! :-)”
Conference sessions focused on Technical Innovation, Community & Contribution, Security & Compliance, and Business Value & Adoption. Topics included post-quantum cryptography (PQC), FIPS 140-3 validation, TLS 1.3 deployment, and open-source governance, with presentations from Keyfactor, ToneFlow, Access Now, Oracle, cryptlib and more.
Building on the success of the inaugural 2025 event, the 2026 conference will bring together leading experts in cryptography, cybersecurity, and open-source development to advance. It will continue to connect the technologies and communities that strengthen digital security and remains the central meeting point for those shaping the future of open security from open-source projects like the OpenSSL Project and Bouncy Castle to enterprises, researchers, and standards organisations.
Sponsorships for 2026 are now open. Companies committed to advancing security and privacy should confirm sponsorship now to secure placement, visibility, and direct engagement with the global security and cryptography community. Early sponsors will receive priority recognition in all event materials and communications.
To confirm sponsorship, contact info@openssl-conference.org.
CAMBRIDGE, MA / ACCESS Newswire / October 23, 2025 / Moderna, Inc. (Nasdaq:MRNA) today announced that it will host its Investor Event – Analyst Day at 9:00 a.m. ET on Thursday, November 20, 2025.
The event will include presentations from management discussing Moderna’s development and commercial strategy and key business considerations.
A live webcast of the presentation will be available under “Events and Presentations” in the Investors section of the Moderna website
A replay of the webcast will be archived on Moderna’s website for at least 30 days following the presentation.
About Moderna
Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including pioneering work on COVID-19 vaccines.
Moderna’s mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
Media Contacts
Investors: Lavina Talukdar Senior Vice President & Head of Investor Relations 617-209-5834 Lavina.Talukdar@modernatx.com
With the industry’s largest network of sites, Florence sets a new benchmark for AI-enabled study startup, workflow automation, and operational risk management.
ATLANTA, GA / ACCESS Newswire / October 23, 2025 / Florence Healthcare reinforced its position as the global leader in clinical trial operations with a major milestone: Florence Trial Operations Platform now connects 65,000 study sites spanning more than 600 sponsors across 90+ countries, forming the industry’s largest network. Recognized as the #1 clinical trial technology for six consecutive years, Florence continues to set the standard for startup speed, workflow automation, and operational risk management across sponsor study portfolios.
“Florence was built to bring sponsors and sites into a shared operational space,” said Ryan Jones, CEO of Florence Healthcare. “First, we fully digitized startup to eliminate manual bottlenecks and paper workflows. Now, we’re using AI to enhance speed and augment intelligence across 65,000 study sites globally – arming sponsors with portfolio-wide operational visibility so they can anticipate trial risk, act on insights, and drive execution on the ground.”
Solving the $1 million per study problem
While digital-first sites set new standards for operational speed and efficiency, much of the industry still remains offline. Only 30% of global sites currently use an eISF, leaving roughly 200,000 sites dependent on inefficient paper processes for study startup, document collection and storage, regulatory process management, monitoring and closeout.
This lack of digitization costs sponsors an estimated $1 million per study in lost productivity, rework, quality and compliance risk.
Florence is closing this digital divide through the fastest growing clinical research network of 65,000 study sites and 600+ sponsors. By digitizing 100% of operational workflows, Florence sets the standard for startup speed, operational cost reduction, and risk control.
The results are compelling:
Up to 70% faster last mile study startup operations compared to the average site startup time for a Top 10 global pharmaceutical sponsor.
$141M annual operational cost takeout by automating site readiness workflows, based on active daily users and total hours saved per year across Florence’s study site network.
51% increase in eTMF QA pass rates from 65% to 98.7%, due to built-in operational audits and automated compliance checks to control risk.
Shaping the Future of Study Operations
Florence is embedding AI across the study lifecycle to unlock operational data intelligence, recommend next-best actions, strengthen risk control, and improve operating efficiency.
Site Identification & Feasibility
Drawing on the industry’s largest network of site intelligence, Florence enables sponsors and CROs to identify the most qualified sites by therapeutic area, geography, and performance, while AI-assisted feasibility surveys ensure faster, more accurate completion.
Study Startup
AI-enabled contracting and document exchange between eTMF and eISF automates SSU document exchange, while generative AI redlining shortens contract review cycles, compares terms in seconds, and dramatically reduces time to activation.
Remote Monitoring
AI-powered reporting surfaces early risk signals from operational audit trails and site data, providing real-time visibility and enabling proactive intervention. These insights minimize the need for on-site visits and ensure trials stay on schedule.
Together, these advancements move sponsors and CROs from manual oversight to intelligent execution across global study portfolios. Through its open API network, Florence rapidly integrates and extends its trial operation capabilities to other eClinical partner systems.
Florence AI operates at the speed of trust, ensuring every study remains fully aligned with FDA, EMA, HIPAA, GDPR, EU Annex 11, ICH E6 (R3), and GCP standards.
All capabilities will be available in December 2025.
Join the Movement: Research Revolution 2025
Florence will showcase its newest capabilities at Research Revolution 2025, the company’s annual global event (October 26-28, 2025) bringing together sponsors, CROs, and research sites. Be part of the global revolution. Watch it live at: https://researchrevolutionsummit.com/live/
About Florence Healthcare
Florence is a purpose-built platform that connects sponsors and sites to accelerate clinical trials, improve operational capacity, and reduce risk. Designed for scale, Florence streamlines workflows, enhances collaboration, and delivers real-time visibility across studies-empowering research teams to move faster, stay inspection-ready, and increase trial throughput with fewer resources.
Global live streaming viewership grew 13% year-over-year to 9.6B hours watched during Q3 2025, reflecting the highest Q3 viewership ever across all live-streaming platforms
FRISCO, TX / ACCESS Newswire / October 23, 2025 / Stream Hatchet, the leading provider of data analytics for the live streaming and gaming ecosystem and wholly-owned subsidiary of GameSquare Holdings (NASDAQ:GAME), (“GameSquare”, or the “Company”), has released its Q3 2025 Live Streaming Trends Report. The report reveals key insights into the evolution of the global live streaming market across gaming, esports, and entertainment.
“Live streaming continues to expand beyond gaming as it becomes a powerful force for the future of live entertainment,” said Justin Kenna, CEO of GameSquare. “With TikTok Live surpassing Twitch in total hours watched and events like the Esports World Cup and Kai Cenat’s Mafiathon setting new benchmarks for engagement, we’re witnessing a massive reallocation of attention. These trends validate our belief that creators and interactive formats are driving the next generation of media.”
Key Insights from Stream Hatchet’s Q3 2025 Report:
Twitch dropped below 50% market share for the first time ever, partially due to viewbotting crackdowns (but remains the most-viewed platform)
TikTok Live data is in, and the mobile platform brought in 9.2B hours watched in Q3 2025 compared to 4.6B for Twitch – a major shift in perception for where audiences find streaming
The Esports World Cup grew stronger, with the Saudi-backed global gaming event reaching 168M hours watched – up 73% from 2024
Subathon 2025 reached record levels with Kai Cenat as the big winner: His Mafiathon 3 marathon stream brought in 71% of all Subtember subs
Live-streaming is the place for sports: As just one example, FC Barcelona hit 3.2M viewers for their match against Como 1907
For more information on Stream Hatchet and insight into the esports and streaming markets, please visit their website at www.streamhatchet.com.
About GameSquare Holdings, Inc.
GameSquare (NASDAQ:GAME) is a cutting-edge media, entertainment, and technology company transforming how brands and publishers connect with Gen Z, Gen Alpha, and Millennial audiences. With a platform that spans award-winning creative services, advanced analytics, and FaZe Clan Esports, one of the most iconic gaming organizations, we operate one of the largest gaming media networks in North America. As a digital-native business, GameSquare provides brands with unparalleled access to world-class creators and talent, delivering authentic connections across gaming, esports, and youth culture. Complementing our operating strategy, GameSquare has developed an innovative treasury management program designed to generate yield and enhance capital efficiency, reinforcing our commitment to building a dynamic, high-performing media company at the intersection of culture, technology, and next-generation financial innovation.
Stream Hatchet delivers real-time, actionable insights into the gaming and live-streaming ecosystem across 16 platforms. From performance benchmarking to campaign ROI and influencer intelligence, Stream Hatchet empowers game publishers, brands, agencies, and tournament organizers with the industry’s most granular data and reporting tools.
This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate, among other things, to: the Company’s future performance, revenue, growth and profitability; and the performance of the live streaming market . These forward-looking statements are provided only to provide information currently available to us and are not intended to serve as and must not be relied on by any investor as, a guarantee, assurance or definitive statement of fact or probability. Forward-looking statements are necessarily based upon a number of estimates and assumptions which include, but are not limited to: the Company’s ability to grow their business and being able to execute on their business plans, the Company being able to complete and successfully integrate acquisitions, the Company being able to recognize and capitalize on opportunities and the Company continuing to attract qualified personnel to supports its development requirements. These assumptions, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: the Company’s ability to achieve its objectives, the Company successfully executing its growth strategy, the ability of the Company to obtain future financings or complete offerings on acceptable terms, failure to leverage the Company’s portfolio across entertainment and media platforms, dependence on the Company’s key personnel and general business, economic, competitive, political and social uncertainties. These risk factors are not intended to represent a complete list of the factors that could affect the Company which are discussed in the Company’s most recent MD&A. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. GameSquare assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.
Corporate Contact Lou Schwartz, President Phone: (216) 464-6400 Email: ir@gamesquare.com
Investor Relations Andrew Berger Phone: (216) 464-6400 Email: ir@gamesquare.com
Media Relations Chelsey Northern / The Untold Phone: (254) 855-4028 Email: pr@gamesquare.com
SINGAPORE, SG / ACCESS Newswire / October 22, 2025 / Immortal Dragons, a $40 million longevity fund, announced its strategic investment in Unlimited Bio, a biotechnology company developing combinatorial therapies to address the multi-system nature of aging.
Combinatorial Therapeutic Strategy
Unlimited Bio’s platform integrates gene therapies, biologics, plasma-based interventions, cell therapies, and small-molecule programs targeting complementary mechanisms across organ systems. The company employs both repurposed approved compounds and proprietary candidates developed in-house.The approach is based on the premise that aging results from the concurrent failure of multiple interconnected biological systems, requiring a synergistic, large-scale combination of interventions acting across tissues and pathways.The initial gene therapy portfolio includes VEGF-A and Follistatin for vascular and muscular applications, and α-Klotho and BDNF for cognitive and neuroprotective applications VEGF-A gene therapy -an approved drug repurposed for vascular rejuvenation-has demonstrated up to ~7.5-fold (756%) increases in pain-free walking distance in patients with peripheral ischemia 1 and has been used in thousands of patients since 2011, 2 providing one of the more extensive post-marketing safety data sets among gene therapies in clinical use. 3
“Aging is not a single pathway but a multi-system failure involving interdependent biological networks.” explained Ivan Morgunov, CEO of Unlimited Bio, “Our philosophy views this problem as an engineering challenge that demands an integrated, synergistic system-ultimately enabling safe combinations of dozens of interventions.”
Strategic Alignment
This investment advances Immortal Dragons’ engineering-centric approach to radical life extension. While the fund’s existing portfolio addresses organ failure through 3D biofabrication and artificial womb technology, Unlimited Bio’s platform targets the underlying mechanisms of biological aging-potentially extending functional lifespan of both natural and engineered tissues.
Further clinical validation will proceed through Special Economic Zones, specifically Prospera ZEDE, utilizing surrogate endpoints in healthy volunteers to enable cost-efficient trials meeting high safety standards.
Looking Ahead
Unlimited Bio’s near-term priority is the first-in-human clinical study combining two gene therapies in healthy participants – planned for late 2025 to early 2026, pending regulatory and ethics approvals. This study is described as the first clinical evaluation of a dual gene-therapy combination in healthy individuals and is aimed to serve as a proof-of-concept demonstrating the safety and synergistic rejuvenative potential of multi-gene interventions. Building on this foundation, the company will expand toward integrated therapeutic combinations across molecular, cellular, and systemic levels, creating a platform capable of continuously incorporating emerging longevity discoveries and optimizing intervention synergies over the next decade.
About Immortal Dragons
Immortal Dragons (https://www.id.life/) is a purpose-driven longevity fund headquartered in Singapore. The fund invests in cutting-edge, high-impact technologies and currently supports more than 15 portfolio companies. Beyond conventional investments, the fund advances longevity advocacy through book translation and publishing, translation of longevity leaders’ talks, hosting a leading Chinese-language longevity podcast, and providing sponsorships and grants to longevity initiatives and conferences.
Erik Gershwind to Retire as CEO and Remain on Board as Non-Executive Vice Chair
Martina McIsaac to Succeed Erik Gershwind as CEO
MELVILLE, NY AND DAVIDSON, NC / ACCESS Newswire / October 23, 2025 / MSC Industrial Supply Co. (NYSE:MSM), a premier distributor of Metalworking and Maintenance, Repair and Operations (MRO) products and services to industrial customers throughout North America, today announced that Martina McIsaac, MSC’s current President and Chief Operating Officer, will succeed Erik Gershwind as Chief Executive Officer, effective January 1, 2026, and maintain her role as President. Following his planned retirement as Chief Executive Officer, Mr. Gershwind will continue to serve the Company as non-executive Vice Chair of the Board of Directors while Mitchell Jacobson remains the Company’s non-executive Chairman of the Board of Directors. Ms. McIsaac will also join the MSC Board of Directors upon assuming her new role as President and Chief Executive Officer.
The leadership transition reflects MSC’s commitment to succession planning, positioning the organization for sustained growth, and value creation. Ms. McIsaac is a seasoned executive most recently responsible for overseeing the operational and strategic direction of the Company across Sales, Field Service/Solutions, Category Management, Procurement, Pricing, Supply Chain, Sustainability, and Information Technology.
“On behalf of the entire Board, I want to express our deepest gratitude to Erik for thirteen years of exceptional leadership and unwavering dedication as CEO,” said Steven Paladino, Lead Independent Director. “Erik has shaped the Company’s direction and growth path, leading MSC’s transformation from a spot-buy supplier into a mission critical partner on the plant floor of industrial customers. He focused relentlessly on helping customers solve their Mission Critical challenges while leading strategic investments in people, technology, and acquisitions that drove substantial growth. We thank him for his leadership and are pleased he will continue to serve as Vice Chair of the Board.”
Mitchell Jacobson, the Company’s non-executive Chairman of the Board of Directors, said, “We are excited for Martina to serve as MSC’s next leader. The Board has worked closely with her over the past three years and has tremendous confidence in her. She has demonstrated a track record of operational execution and has built strong relationships with our customers, suppliers, and all stakeholders. She will build on recent momentum and drive the innovation and growth necessary to achieve our Mission Critical objectives.”
Erik Gershwind, Chief Executive Officer, said, “Reflecting on nearly thirty years with MSC and thirteen years as CEO, I am proud of what our team has accomplished. The culture we have molded and the strategies we have implemented set the company up for great success moving forward. It has been an honor to lead this company, and I want to thank Steve and our Board for their trust and guidance. I’m excited to continue supporting the Company as Vice Chair of the Board.”
Mr. Gershwind continued, “Martina has demonstrated exceptional leadership and vision, and I am confident in her ability to lead MSC into its next phase of growth. During her tenure thus far, we have improved execution, strengthened our market position, and enhanced our customer value proposition.”
Martina McIsaac, President and Chief Operating Officer concluded, “I am honored by the Board’s confidence and excited to step into this expanded role, leading MSC into its next chapter. Over the past three years, I’ve had the privilege of working alongside an exceptional team of associates that deliver for our customers day in and day out. I am energized by the opportunities ahead to accelerate growth, build on our strong foundation, and fulfill our mission to be the best industrial distributor for our associates, customers, suppliers, and shareholders.”
Martina McIsaac is President and Chief Operating Officer of MSC Industrial Supply Co. In this role, she has overall responsibility for the entirety of MSC’s day-to-day operations, which include Sales, Field Service/Solutions, Category Management, Procurement, Pricing, Supply Chain, Sustainability and Information Technology.
Ms. McIsaac joined MSC in 2022 as Executive Vice President and Chief Operating Officer and in 2024 was appointed as MSC’s President and Chief Operating Officer. Prior to joining MSC, Ms. McIsaac served a nine-year tenure with Hilti Corporation, a multinational company that develops, manufactures and markets hardware, software and services for the construction, building maintenance, energy and manufacturing industries. Most recently, she served as Region Head and Chief Executive Officer of Hilti, Inc., leading the North America organization. Prior to joining Hilti, Ms. McIsaac held a series of progressively responsible leadership roles with Avery Dennison, a Fortune 500 global materials science and manufacturing company. During her 14-year tenure with Avery Dennison, Ms. McIsaac served in a range of sales, marketing, business development and operational roles in Mexico, Argentina, Chile, Canada and the U.S. prior to being named Vice President and General Manager of the Performance Polymers Division.
Ms. McIsaac holds a bachelor’s degree in economics from Western University and a master’s degree in international business from the University of South Carolina, where she serves on the board of the Folks Center for International Business. Ms. McIsaac is a signatory to the Catalyst CEO Champions for Change pledge, joining other high-profile leaders who are personally committed to helping organizations solve business challenges by attracting and retaining talent, fostering innovation and driving performance. She is a member of the Appalachian State University Supply Chain Advisory Board, the Texas Women’s Foundation’s Economic Leadership Council, a past chair of the Dallas Habitat for Humanity Women Build and past member of the Board of Directors for United Way of Metropolitan Dallas.
About MSC Industrial Supply Co.
MSC Industrial Supply Co. (NYSE:MSM) is a leading North American distributor of a broad range of metalworking and maintenance, repair and operations (MRO) products and services. We help our customers drive greater productivity, profitability and growth with approximately 2.5 million products, inventory management and other supply chain solutions, and deep expertise from more than 80 years of working with customers across industries. Our experienced team of more than 7,000 associates works with our customers to help drive results for their businesses – from keeping operations running efficiently today to continuously rethinking, retooling and optimizing for a more productive tomorrow. For more information on MSC Industrial, please visit mscdirect.com.
Statements in this press release may constitute “forward-looking statements” under the Private Securities Litigation Reform Act of 1995. All statements, other than statements of present or historical fact, that address activities, events or developments that MSC expects, believes or anticipates will or may occur in the future, including statements about results of operations and financial condition, expected future results, expected benefits from our investment and strategic plans and other initiatives, and expected future growth and profitability, are forward-looking statements. The words “will,” “may,” “believes,” “anticipates,” “thinks,” “expects,” “estimates,” “plans,” “intends” and similar expressions are intended to identify forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those anticipated by these forward-looking statements. In addition, statements which refer to expectations, projections or other characterizations of future events or circumstances, statements involving a discussion of strategy, plans or intentions, statements about management’s assumptions, projections or predictions of future events or market outlook and any other statement other than a statement of present or historical fact are forward-looking statements. The inclusion of any statement in this press release does not constitute an admission by MSC or any other person that the events or circumstances described in such statement are material. In addition, new risks may emerge from time to time and it is not possible for management to predict such risks or to assess the impact of such risks on our business or financial results. Accordingly, future results may differ materially from historical results or from those discussed or implied by these forward-looking statements. Given these risks and uncertainties, the reader should not place undue reliance on these forward-looking statements. These risks and uncertainties include, but are not limited to, the following: general economic conditions in the markets in which we operate; changing customer and product mixes; volatility in commodity, energy and labor prices, and the impact of prolonged periods of low, high or rapid inflation; competition, including the adoption by competitors of aggressive pricing strategies or sales methods; industry consolidation and other changes in the industrial distribution sector; the applicability of laws and regulations relating to our status as a supplier to the U.S. government and public sector; the credit risk of our customers; our ability to accurately forecast customer demands; interruptions in our ability to make deliveries to customers; supply chain disruptions; our ability to attract and retain sales and customer service personnel; the risk of loss of key suppliers or contractors or key brands; changes to trade policies or trade relationships, including tariff policies; risks associated with opening or expanding our customer fulfillment centers; our ability to estimate the cost of healthcare claims incurred under our self-insurance plan; interruption of operations at our headquarters or customer fulfillment centers; products liability due to the nature of the products that we sell; impairments of goodwill and other indefinite-lived intangible assets; the impact of climate change; operating and financial restrictions imposed by the terms of our material debt instruments; our ability to access additional liquidity; the significant influence that our principal shareholders will continue to have over our decisions; our ability to execute on our E-commerce strategies and maintain our digital platforms; costs associated with maintaining our information technology (“IT”) systems and complying with data privacy laws; disruptions or breaches of our IT systems or violations of data privacy laws, including such disruptions or breaches in connection with our E-commerce channels; risks related to online payment methods and other online transactions; our ability to remediate a material weakness in our internal control over financial reporting and to maintain effective internal control over financial reporting and our disclosure controls and procedures in the future; the retention of key management personnel; litigation risk due to the nature of our business; failure to comply with environmental, health, and safety laws and regulations; and our ability to comply with, and the costs associated with, social and environmental responsibility policies. Additional information concerning these and other risks is described under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual and Quarterly Reports on Forms 10-K and 10-Q, respectively, and in the other reports and documents that we file with the United States Securities and Exchange Commission. We expressly disclaim any obligation to update any of these forward-looking statements, except to the extent required by applicable law.
LISBON, PT AND WEST PALM BEACH, FL / ACCESS Newswire / October 23, 2025 / USPA Global today announced that U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), has been awarded two prestigious Stevie® Awards from the 22nd Annual International Business Awards® (IBA).
U.S. Polo Assn. was celebrated during an elegant gala event at the Corinthia Hotel in Lisbon, Portugal, on Friday, October 10, attended by leadership from USPA Global and the brand’s strategic partners in the region. The global event hosted over 350 guests from more than 30 nations, including many of the world’s top companies and Stevie winners, including Coca-Cola, Starbucks, Lenovo, Kendra Scott, IBM, and Turkish Airlines.
The brand’s winning entries included a Gold Stevie Award for ‘Achievement in International Expansion’ and a Silver Stevie Award in ‘Celebration Event’ for the 2024 Paris Games Polo Challenge campaign. The multi-billion-dollar, sport-inspired global brand received high scores from the judges over all submissions in these very competitive global growth categories. Accepting the two trophies on stage were Stacey Kovalsky, Vice President, Global PR and Communications, and Yesim Ilgun for USPA Global; Franco Zuccon, CEO, Eurotrade; Augusto Bonetto, CEO, Bonis; Alessia Lana, Incom; Filippo Peroni and Enrica Cova, Eastlab.
“For U.S. Polo Assn. to win both Gold and Silver Stevie Awards from the 22nd Annual International Business Awards is a tremendous recognition of our brand’s global prowess and creative strength,” said J. Michael Prince, President and CEO of USPA Global, the company that manages the multi-billion-dollar U.S. Polo Assn. brand. “We are especially proud to be recognized for our international expansion strategy, which includes efforts from all of U.S. Polo Assn.’s strategic global partners, and for the Paris Games Polo Challenge, a one-of-a-kind global campaign that celebrated the heritage of the sport on an historic, world sports stage.”
The Gold Award for ‘Achievement in International Expansion’ acknowledges U.S. Polo Assn.’s $2.5 billion in global retail sales across 190 countries, with more than 1,200 branded retail stores and a strong e-commerce presence in more than 50 countries in 20 different languages. The Silver Award for ‘Celebration Event’ highlights the brand’s groundbreaking Paris Games Polo Challenge 2024, a centennial celebration and sanctioned tribute match between the USA and France at the Polo Club du Domaine Chantilly. Both awards, altogether, strengthen U.S. Polo Assn.’s authentic connection to the sport of polo and consumers worldwide.
The International Business Awards are widely recognized as the world’s premier business awards program. The 2025 IBAs attracted entries from organizations spanning nearly 80 nations and territories, with more than 3,800 nominations from organizations of all sizes and virtually every industry submitted across a wide range of categories this year. Stevie Award winners were determined by the average scores of more than 250 executives worldwide who participated in the three-month judging process.
Details about the 22nd Annual International Business Awards and the complete list of 2025 Stevie Award winners are available at StevieAwards.com/IBA.
About U.S. Polo Assn. and USPA Global
U.S. Polo Assn. is the official sports brand of the United States Polo Association (USPA), the largest association of polo clubs and polo players in the United States, founded in 1890 and based at the USPA National Polo Center (NPC) in Wellington, Florida. This year, U.S. Polo Assn. celebrates 135 years of sports inspiration alongside the USPA. With a multi-billion-dollar global footprint and worldwide distribution through more than 1,200 U.S. Polo Assn. retail stores as well as thousands of additional points of distribution, U.S. Polo Assn. offers apparel, accessories, and footwear for men, women, and children in more than 190 countries worldwide. The brand sponsors major polo events around the world, including the U.S. Open Polo Championship®, held annually at NPC in The Palm Beaches, the premier polo tournament in the United States. Historic deals with ESPN in the United States, TNT and Eurosport in Europe, and Star Sports in India now broadcast several of the premier polo championships in the world, sponsored by U.S. Polo Assn., making the thrilling sport accessible to millions of sports fans globally for the very first time.
U.S. Polo Assn. has consistently been named one of the top global sports licensors in the world alongside the NFL, PGA Tour, and Formula 1, according to License Global. In addition, the sport-inspired brand is being recognized internationally with awards for global growth. Due to its tremendous success as a global brand, U.S. Polo Assn. has been featured in Forbes, Fortune, Modern Retail, and GQ as well as on Yahoo Finance and Bloomberg, among many other noteworthy media sources around the world.
USPA Global is a subsidiary of the United States Polo Association (USPA) and manages the multi-billion-dollar sports brand, U.S. Polo Assn. USPA Global also manages the subsidiary, Global Polo, which is the worldwide leader in polo sport content. To learn more, visit globalpolo.com or Global Polo on YouTube.
###
Contact Information
Stacey Kovalsky VP, Global PR and Communications skovalsky@uspagl.com +001.561.790.8036
VANCOUVER, BC / ACCESS Newswire / October 23, 2025 / North Shore Uranium Ltd. (TSXV:NSU) (“North Shore” or the “Company“) is pleased to announce that it has met its final earn-in obligation for the West Bear property (“West Bear“)under an option agreement dated April 18, 2022 (as amended, the “West Bear Option Agreement“) with Gem Oil Inc. (“Gem Oil“), giving the Company the right to acquire a 75% interest in West Bear. West Bear consists of four mining claims totaling 3,927 hectares at the eastern margin of the Athabasca Basin in Saskatchewan.
To satisfy the final $50,000 payment for West Bear, the Company issued 263,157 common shares (the “Option Shares“) at a deemed price of $0.19 per share to Gem Oil. The Options Shares were issued in accordance with the West Bear Option Agreement and are subject to a statutory hold period under applicable Canadian securities laws and a TSX Venture Exchange hold period, both expiring four months and one day from the date of issuance (February 23, 2026). Upon completion of this payment, North Shore has earned a 75% interest in West Bear and a joint venture will be formed with North Shore holding a 75% interest and Gem Oil holding a 25% interest. Gem Oil will be granted a 2% net smelter returns royalty (“NSR“), of which North Shore may purchase 1% for $1,000,000 at any time. North Shore retains the right to acquire the remaining 25% interest in West Bear by paying Gem Oil $200,000 in cash and issuing $200,000 in North Shore common shares within 90 days of delivering the Initial Interest Notice to Gem Oil. If North Shore does not exercise this right within the 90-day period, or fails to complete the acquisition, a participating joint venture will be formed as described above.
West Bear is located approximately 35 km southeast of the Cigar Lake uranium mine, and 50 km south of the McClean Lake uranium mill. The West Bear uranium and cobalt-nickel deposits held by Uranium Energy Corp. (“UEX/UEC“) are located just north of the property (Figure 1 below). The unconformity between the Athabasca Basin sandstone and the underlying basement rocks crosses the western portion of the property (Figure 1). West Bear saw significant uranium exploration activity between the 1960s and 2015, with a total of 15 exploration holes being drilled, including three by Denison in 2015. Historical exploration data evaluated by the Company includes high-resolution electromagnetic airborne geophysical surveys. In 2022 North Shore completed a gravity-magnetic-radiometric airborne survey over West Bear. The Company has selected several targets that warrant further exploration and evaluation of all exploration data is ongoing.
ABOUT NORTH SHORE
The nuclear power industry is in growth mode as more nuclear power will be required to meet the world’s ambitious CO2 emission-reduction goals and the needs of new power-intensive technologies like AI. In this environment, new discoveries of economic uranium deposits could be very valuable, especially in established uranium-producing jurisdictions like Saskatchewan and New Mexico. North Shore is well-positioned to become a major force in exploration for economic uranium deposits. The Company is working to achieve this goal by exploring its Rio Puerco project in the Grants Uranium District of New Mexico and the Falcon and West Bear properties at the eastern margin of the Athabasca Basin in Saskatchewan. In addition, the Company continues to evaluate quality opportunities in the United States and Canada to complement its portfolio of uranium properties.
Figure 1. West Bear property and neighboring property positions. Source: Saskatchewan government database on September 15, 2025 and company disclosure. This figure contains information about properties adjacent to West Bear which North Shore does not have the right to explore. Investors are cautioned that mineralization on adjacent properties is not necessarily indicative of mineralization at West Bear.
Technical information on the West Bear property is provided in the 2023 technical report entitled “Technical Report for the West Bear Property, Saskatchewan, Canada” filed under the profile of North Shore Uranium at www.sedarplus.ca.
QUALIFIED PERSON
Mr. Brooke Clements, MSc, P.Geol., a Qualified Person as defined by National Instrument 43-101 – Standards of Disclosure for Mineral Projects and the President and CEO of North Shore, has reviewed and approved the scientific and technical disclosure in this press release.
ON BEHALF OF THE BOARD
Brooke Clements, President, Chief Executive Officer and Director
For further information please contact: Brooke Clements, President, Chief Executive Officer and Director
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains forward-looking statements relating specifically to the West Bear Property earn-in and the Company’s broader exploration strategy. Forward-looking statements in this release include: the formal completion of the West Bear property earn-in from Gem Oil Inc.; the issuance of common shares to satisfy the final property payment; the formation of a joint venture with Gem Oil and the grant of a net smelter returns royalty; North Shore’s right to acquire the remaining 25% interest in West Bear; the identification of several exploration targets at West Bear; the Company’s belief that it is well-positioned to become a major force in exploration for economic uranium deposits; the Company’s ongoing work to achieve this goal by exploring the Rio Puerco project in New Mexico and the Falcon and West Bear properties in Saskatchewan; and the Company’s continued evaluation of additional uranium opportunities in the United States and Canada. These statements are subject to specific risks and uncertainties, including: the risk that the West Bear Property earn-in may not be completed as anticipated; the risk that the joint venture may not be formed or operated as planned; the risk that North Shore may not exercise its right to acquire the remaining 25% interest; the risk that identified exploration targets may not yield economically viable mineral deposits upon further exploration or drilling; the potential for delays or changes in exploration plans due to environmental conditions, permitting requirements, or logistical challenges in accessing certain areas of the West Bear Property; and the reliance on historical data and previous exploration results, which may have limitations or uncertainties that affect current interpretations. Forward-looking statements are frequently characterized by words such as “plan”, “project”, “appear”, “interpret”, “coincident”, “potential”, “confirm”, “suggest”, “evaluate”, “encourage”, “likely”, “anomaly”, “continuous” and variations of these words as well as other similar words or statements that certain events or conditions “could”, “may”, “should”, “would” or “will” occur. These statements are subject to various risks and uncertainties that may cause actual results to differ materially from those anticipated or implied, including, but not limited to: the speculative nature of mineral exploration and development projects; the ability to obtain necessary permits and approvals; changes in project plans and parameters; variations in mineral grades and recovery rates; accidents, labour disputes and other risks of the mining industry; the availability of funding on terms acceptable to the Company; delays in obtaining governmental approvals or financing; fluctuations in uranium and other metal prices; and other factors described in the Company’s public disclosure documents. There may be other factors that cause actual results, performance, or achievements to differ materially from those anticipated or implied by the forward-looking statements. Any forward-looking statement speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events, or results or otherwise. Forward-looking statements are not guarantees of future performance and undue reliance should not be put on such statements due to the inherent uncertainty therein. Any forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.
New findings highlight Telomir-1’s impact on CASP8 and GSTP1, two critical genes that regulate cell death and glutathione-based detoxification pathways often disrupted in cancer.
MIAMI, FLORIDA / ACCESS Newswire / October 23, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) (“Telomir” or the “Company”), a pre-clinical biotechnology company developing therapies that target the epigenetic roots of cancer, aging, and age-related disease, today reported new preclinical data from an in vivo study in mice bearing human aggressive prostate cancer tumors evaluating DNA-methylation changes in two key defense genes – CASP8 and GSTP1 – following treatment with oral Telomir-1, Rapamycin, chemotherapy, and combination regimens.
Apoptosis (“kill”) and detoxification (“clean”) pathways are two of the body’s fundamental defense systems against cancer initiation and progression, and Telomir-1’s observed modulation of these pathways through DNA-methylation control may represent an important area of ongoing scientific evaluation in oncology research.
Overview of Findings
The study examined DNA methylation, a central epigenetic process that helps determine whether genes are active or silenced. In this model, baseline tumor samples exhibited DNA hypermethylation of CASP8 and GSTP1, a pattern often associated with reduced activity in genes involved in apoptosis and detoxification.
CASP8 (Apoptosis Pathway) CASP8 helps initiate programmed cell death. Telomir-1 treatment was associated with reduced methylation of the CASP8 promoter at Day 10 and 21 relative to vehicle and chemotherapy group, suggesting potential reactivation of apoptotic pathway control.
GSTP1 (Detoxification and Glutathione Pathway) GSTP1 encodes glutathione S-transferase Pi 1, an enzyme that uses glutathione (GSH) – one of the body’s most important natural antioxidants – to neutralize reactive oxygen species and chemical stress. Telomir-1 was associated with decreased DNA-methylation of GSTP1 compared with vehicle and chemotherapy, consistent with partial restoration of this critical detoxification and antioxidant defense system.
Chemotherapy Alone Chemotherapy did not appear to reduce methylation of either gene, consistent with prior observations that certain cytotoxic agents can reinforce methylation stress – a process that may contribute to taxane resistance (reduced tumor response to chemo drugs like paclitaxel) driven by transcriptional and epigenetic rewiring.
Combination of Chemotherapy + Telomir-1 When Telomir-1 was administered with chemotherapy, both CASP8 and GSTP1 showed lower methylation than with chemotherapy alone, suggesting that Telomir-1 may help counteract chemotherapy related epigenetic silencing in this setting.
Why These Pathways Matter in Cancer Biology
Apoptosis and detoxification represent two of the body’s most fundamental defense systems against cancer initiation and progression.
Apoptosis – the “Kill System” This pathway allows damaged or abnormal cells to self-destruct before they proliferate. In many cancers, genes such as CASP8 become silenced through abnormal DNA methylation, preventing programmed cell death and enabling tumor survival and resistance to therapy.
Detoxification – the “Clean System” The GSTP1 glutathione axis helps remove oxidative and chemical stress that accumulates during inflammation, environmental exposure, or treatment. When DNA sequence for GSTP1 is hypermethylated and silenced, cells lose part of this antioxidant capacity, leading to higher oxidative stress and DNA instability. Supporting glutathione related detoxification may reduce the cellular conditions that favor tumor persistence and therapy resistance.
By addressing both apoptotic and detoxification imbalances through DNA methylation modulation, Telomir-1 may engage two complementary mechanisms commonly disrupted in cancer biology.
Rapamycin Comparison
At earlier observation points (Day 10), Rapamycin – an mTOR-pathway inhibitor – was associated with an initial reduction in DNA methylation for both genes. This observation aligns with Rapamycin’s indirect influence on cellular metabolism and oxidative stress, which can temporarily affect DNA methylating enzyme activity. By Day 21, methylation levels partially rebounded, suggesting that the effect may have been transient and metabolically driven rather than a direct epigenetic reset.
Telomir-1, by contrast, was associated with a progressive and more sustained decrease in methylation through Day 21. Unlike Rapamycin, Telomir-1 is believed to interact with epigenetic regulatory enzymes that add or remove methyl groups from DNA and histones, which may contribute to the durability of its observed effects in this preclinical model.
Interpretation
Collectively, these preclinical observations indicate that Telomir-1 influenced two complementary cellular pathways – apoptosis and detoxification – through DNA methylation modulation not observed with chemotherapy and more sustained than that seen with Rapamycin. The data suggest Telomir-1 may act at the level of epigenetic enzyme regulation, whereas Rapamycin’s effects appear secondary to metabolic signaling. Further studies are planned to clarify these mechanisms and their potential relevance for oncology research.
Scientific Perspective
“This preclinical work, which supports earlier studies with Telomir-1 on DNA methylation in cancer, helps differentiate the epigenetic modulation observed with Telomir-1 from the indirect metabolic effects of Rapamycin,” said Dr. Itzchak Angel, CSA at Telomir. “By evaluating DNA methylation dynamics in apoptosis and detoxification pathways, we are building a scientific framework for understanding how Telomir-1 may help restore epigenetic balance in cancer models.“
CEO Perspective
“Our goal is to develop medicines that don’t just treat what cancer becomes but help reset the biology that lets it begin. Telomir-1 may represent that next frontier.“ – Erez Aminov, CEO, Telomir
About Telomir Pharmaceuticals
Telomir Pharmaceuticals (NASDAQ:TELO) is a pre-clinical stage biotechnology company developing therapies designed to target the root epigenetic mechanisms underlying cancer, aging, and degenerative disease. The Company’s lead candidate, Telomir-1, has demonstrated activity in preclinical studies involving modulation of DNA and histone methylation patterns, which may contribute to balanced gene expression, cellular function, and genomic stability. For more information, please visit www.telomirpharma.com.
This press release, statements of Telomir’s management or advisors related thereto, and the statements contained in the news story linked in this release contain “forward-looking statements,” which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications, and the safety of Telomir-1.
Any forward-looking statements in this press release are based on Telomir’s current expectations, estimates and projections only as of the date of this release. These and other risks concerning Telomir’s programs and operations are described in additional detail in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which are on file with the SEC and available at www.sec.gov. Telomir explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
